BD and ChemoGLO™ Collaborate to Expand Hazardous Drug Contamination Testing for Health Care Facilities and Laboratories
Rhea-AI Summary
BD (NYSE: BDX) and ChemoGLO announced a strategic collaboration to expand hazardous drug contamination testing for health care facilities and laboratories.
The partnership pairs the BD HD Check System — providing qualitative, point-of-care results in 10 minutes — with ChemoGLO's LC-MS/MS quantitative analysis, which delivers an expanded hazardous‑drug panel report within 3–5 days after sample receipt. The workflow uses BD HD Check collection kits for safe shipping to ChemoGLO for follow-up testing.
The combined approach aims to help facilities quickly identify contamination and gain deeper quantitative insights to better protect health care workers. BD and ChemoGLO will be at the ASHP Midyear Clinical Meeting in Las Vegas, Dec 6–10, 2025 (BD Booth 1017; ChemoGLO Booth 1873).
Positive
- None.
Negative
- None.
Insights
Partnership combines rapid screening with lab confirmation to strengthen hazardous drug surface surveillance and worker safety.
The collaboration pairs BD rapid, point-of-care qualitative screening with ChemoGLO™'s quantitative LC-MS/MS analysis to create a two-step testing pathway: immediate identification in about 10 minutes followed by a detailed quantitative report within
This approach improves detection fidelity by using a quick triage test to direct targeted lab analysis, reducing false reassurance from single-method testing while giving actionable concentration data for remediation efforts; its effectiveness depends on sample chain-of-custody, lab turnaround, and consistent sampling technique.
Watch for uptake signals at the
Streamlined kit-to-lab workflow reduces friction for facilities seeking both fast screening and quantitative confirmation.
The bundled workflow—on-site sampling with the BD HD Check collection kit, safe shipping to ChemoGLO™, and combined reporting—lowers operational barriers for routine contamination monitoring and may increase testing frequency in facilities already constrained by staff and lab access.
Risks include logistical costs of shipping, variability in sampling execution across sites, and the time lag to quantitative results; contractual terms, pricing, and integration of reports into facility quality systems will determine commercial traction.
Monitor adoption rates announced after the
This collaboration allows facilities to combine the rapid, point-of-care qualitative results from the BD® HD Check System – available in just 10 minutes – with ChemoGLO™'s liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis, delivering a comprehensive quantitative report on an expanded panel of hazardous drugs within three to five days after receipt of samples. Once a sample is collected with the HD Check collection kit, it can be safely packaged and shipped to ChemoGLO™ for further analysis.
"With the BD® HD Check System, facilities can quickly identify potential contamination, and through our collaboration with ChemoGLO™, gain deeper insights into exposure risks," said Eric Borin, worldwide president of BD Medication Delivery Solutions. "This dual approach helps pinpoint areas of improvement and reinforces our commitment to health care worker safety."
Together, BD and ChemoGLO™ offer a streamlined sampling and testing workflow that empowers health care facilities to monitor contamination more effectively and take timely action to help protect health care workers from exposure risks. This combined testing approach aligns with recommendations outlined at a 2020 consensus conference on hazardous drug surface contamination, which encourages healthcare institutions to use both qualitative and quantitative surface contamination testing to better assess environmental safety and reduce exposure risks for staff.1
"At ChemoGLO™, the heart of our mission has always been to protect health care workers and patients from hazardous drug exposure," said Cara Zamboni, CEO at ChemoGLO™. "By partnering with BD, we're combining speed and precision to help facilities act faster and more confidently to safeguard their teams."
To learn more about the collaboration, visit BD (Booth 1017) and ChemoGLO™ (Booth 1873) at the upcoming American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting in
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
About ChemoGLO™
ChemoGLO™ is at the forefront of healthcare safety specializing in hazardous drug detection, removal, and management solutions. For 20 years, our leading-edge innovations have provided accurate, quantified measurements of surface contamination levels of hazardous drugs, including chemotherapy, in hospitals, pharmacies, laboratories, manufacturing facilities, and other settings. Our ChemoGLO™ Wipe Kit can test for 26 different hazardous drugs and provide accurate, quantified results within 3-5 business days. The ChemoGLO™ Wipe Kit can be customized to meet projects of all types, sizes, and timelines. This easy-to-use testing kit ships at room temperature and is the most widely used testing kit in the world. In addition, ChemoGLO™ has HDClean Towelettes which are laboratory tested and proven to remove surface contamination of chemotherapy agents, hormone drugs, controlled substances, and drugs of abuse. Our mission at ChemoGLO™ is to provide our customers with the highest quality products and services to safeguard your patients, staff, and facilities. For more information on ChemoGLO™, please visit chemoglo.com.
Contacts: | Investors: |
For BD: | |
Alyssa Kretlow | Adam Reiffe |
BD Public Relations | VP, Investor Relations |
551-238-4391 | 201.847.6927 |
For ChemoGLO™: | |
Cara Zamboni | |
CEO | |
919-428-6759 | |
References:
- Gabay M, Johnson P, Fanikos J, et al. Report on 2020 Safe to Touch Consensus Conference on Hazardous Drug Surface Contamination. Am J Health Syst Pharm. 2021;zxab134. doi:10.1093/ajhp/zxab134.
View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-and-chemoglo-collaborate-to-expand-hazardous-drug-contamination-testing-for-health-care-facilities-and-laboratories-302632329.html
SOURCE BD (Becton, Dickinson and Company)
FAQ
What does the BD and ChemoGLO collaboration announced Dec 4, 2025 mean for health care facilities?
How fast does the BD HD Check System provide results for hazardous drug contamination?
How long will ChemoGLO take to return a quantitative hazardous drug report after receiving samples?
Can samples collected with the BD HD Check kit be shipped to ChemoGLO for further testing?
Where and when can investors or facilities learn more about the BD and ChemoGLO collaboration in person?
